Quantcast
Last updated on April 19, 2014 at 8:32 EDT

Latest Levetiracetam Stories

2014-01-09 11:48:50

A new study finds that the epilepsy drug levetiracetam appears not to be associated with thinking, movement and language problems for preschool children born to mothers who took the drug during pregnancy, although the drug valproate was associated with some difficulties in preschoolers. The study is published in the January 8, 2014, online issue of Neurology®, the medical journal of the American Academy of Neurology. "These results are heartening, as the use of levetiracetam has increased...

2013-12-16 12:24:46

Older, Generic Mainstays Will Remain at the Core of Epilepsy Treatment, According to a New Report from Decision Resources BURLINGTON, Mass., Dec. 16, 2013 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that the market for epilepsy pharmacotherapies will expand at a rate of 2 percent annually through 2022, peaking at more than $4.1 billion in 2020. Market growth will be fueled primarily by...

2013-11-20 08:27:50

-- UCB-sponsored data include the first presentation of investigational data of VIMPAT® (lacosamide) as monotherapy for the treatment of partial-onset seizures in adults with epilepsy ATLANTA, Nov. 20, 2013 /PRNewswire/ -- UCB, a global biopharmaceutical company focusing on CNS and immunology treatment and research, will be sponsoring 15 data presentations at the 67th Annual Meeting of the American Epilepsy Society in Washington, D.C., December 6-10. The poster presentations on VIMPAT(®)...

2013-11-04 08:25:48

- Results from VIMPAT® (lacosamide) monotherapy study supporting this filing to be presented at AES 2013 ATLANTA, Nov. 4, 2013 /PRNewswire/ -- UCB announced that the US Food and Drug Administration (FDA) has accepted for filing a supplemental new drug application (sNDA) for VIMPAT(®) (lacosamide) C-V as monotherapy in the treatment of partial-onset seizures in patients with epilepsy aged 17 years and older. Investigational data from the phase 3 lacosamide conversion to monotherapy study in...

2013-09-25 08:30:42

SAN DIEGO, Sept. 25, 2013 /PRNewswire-USNewswire/ -- Current estimates indicate that autism spectrum disorder affects 1 in 88 children, and that the incidence of this disorder is continuing to rise. Medical abnormalities associated with autism are being increasingly recognized. Seizures affect a substantial portion; some estimates suggest that up to 1/3 of children with autism may eventually develop seizures. The incidence of seizures appears to increase with age, becoming more...

2013-06-20 08:25:16

Nearly All Surveyed Payers Report a Willingness to Grant Preferred Formulary Status to Drugs Delivering Such An Improvement, According to a New Report from Decision Resources BURLINGTON, Mass., June 20, 2013 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that surveyed U.S. and European neurologists identify efficacy improvements in the percentage of seizure-free patients as one of the greatest...

2013-04-30 08:35:12

Klitgaard to be Honored at Antiepileptic Drug and Device Trials XII Conference in Miami May 15-17 LANDOVER, Md., April 30, 2013 /PRNewswire-USNewswire/ -- The Epilepsy Foundation announced today that Henrik Klitgaard, Ph.D., Vice President and Fellow, Neurosciences Therapeutic Area, UCB, has been named the recipient of the Epilepsy Therapy Project Lifetime Accelerator Award in recognition of his commitment and contributions to the field of epilepsy and to the people affected by it....

2012-08-07 10:02:05

Scientists at the Gladstone Institutes have discovered that an FDA-approved anti-epileptic drug reverses memory loss and alleviates other Alzheimer's-related impairments in an animal model of the disease. Scientists in the laboratory of Lennart Mucke, MD, who directs neurological research at Gladstone, conducted the research on mice genetically modified to simulate key aspects of Alzheimer's disease. In the study, they show how levetiracetam–a drug commonly prescribed for patients...

2012-07-25 02:30:39

HUNTSVILLE, Ala., July 25, 2012 /PRNewswire-FirstCall/ -- Qualitest Pharmaceuticals today announced that it has received approval from the United States Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Levetiracetam extended-release tablets, 500mg and 750mg, the generic equivalent of UCB's Keppra XR®. The total combined sales for Levetiracetam extended-release tablets, 500mg and 750mg, in the U.S. for the 12 months ending May 31, 2012, were...

2012-04-12 10:22:51

HUNTSVILLE, Ala., April 12, 2012 /PRNewswire-FirstCall/ -- Qualitest Pharmaceuticals today announced that the U.S. Food and Drug Administration has approved Levetiracetam Oral Solution, 100mg/mL. Qualitest plans to begin distribution in mid-2012. The total sales for Levetiracetam Oral Solution, 100mg/mL, in the U.S. for the 12 months ending Dec. 31, 2011, were approximately $62.2 million, according to IMS Health. About Qualitest Founded in 1983, Qualitest provides affordable, high-quality...